Search results for "Hepatitis B Antibodie"

showing 10 items of 50 documents

A head start for life history development? Family income mediates associations between height and immune response in men.

2018

OBJECTIVES Male height and health affect a diverse range of social and economic outcomes such as competition for resources and mates. Life history theory predicts that limited availability of bioenergetic resources curbs the development of central life history functions such as somatic growth, immunity, and investment in offspring. Although genetic factors are important determinants of height, other factors such as income level may affect the incidence of infections during ontogeny, thus having indirect effects on somatic growth. We tested whether growing up in families with a higher income positively affects height and immune function. MATERIALS AND METHODS Seventy-three young Latvian men …

0106 biological sciencesAdultMaleOffspringBiologyFamily incomeAffect (psychology)010603 evolutionary biology01 natural sciencesLife history theoryAnthropology PhysicalYoung AdultHumans0601 history and archaeologyHepatitis B VaccinesHepatitis B AntibodiesSocioeconomic status060101 anthropologyIncidence (epidemiology)Immunity06 humanities and the artsLatviaBody HeightVaccinationSocioeconomic FactorsAnthropologyHead startIncometa1181AnatomyDemographyAmerican journal of physical anthropology
researchProduct

Women's socioeconomic position in ontogeny is associated with improved immune function and lower stress, but not with height

2020

AbstractImmune function, height and resource accumulation comprise important life history traits in humans. Resource availability models arising from life history theory suggest that socioeconomic conditions influence immune function, growth and health status. In this study, we tested whether there are associations between family income during ontogeny, adult height, cortisol level and immune response in women. A hepatitis B vaccine was administered to 66 young Latvian women from different socioeconomic backgrounds, and blood samples were then collected to measure the level of antibodies that the women produced in response to the vaccination. Cortisol levels were measured from plasma sample…

0301 basic medicineAdultHepatitis B vaccineHydrocortisoneOntogenyBiological anthropologyPhysiologylcsh:MedicineBiologyFamily incomeEvolutionary ecologyArticleLife history theory03 medical and health sciencesYoung Adult0302 clinical medicineImmune systemHumansWomenHepatitis B Antibodieslcsh:ScienceSocioeconomic statusMultidisciplinarylcsh:RImmunityLatviaVaccination030104 developmental biologySocial ClassSocioeconomic Factorsbiology.proteinFemalelcsh:QAntibody030217 neurology & neurosurgeryStress PsychologicalCortisol ; Immune function ; Life history theory ; Sexual dimorphism ; Stress
researchProduct

Predictors of Hepatitis B Surface Antigen Titers two decades after vaccination in a cohort of students and post-graduates of the Medical School at th…

2017

Introduction and objective. The introduction of a vaccine against hepatitis B virus (HBV) for newborn babies in Italy in 1991, extended to 12-year-old children for the first 12 years of application, has been a major achievement in terms of the prevention of HBV infection. The objective of this study was to analyse the long-term immunogenicity and effectiveness of HBV vaccination among healthcare students with different working seniorities. Materials and method. A cross-sectional observational study of undergraduate and postgraduate students attending the Medical School of the University of Palermo was conducted from January 2014 – July 2016. HBV serum markers were performed with commercial …

0301 basic medicineMaleHBsAgSettore MED/07 - Microbiologia E Microbiologia ClinicaStudents Medicalmedicine.disease_causeLogistic regressionCohort Studies0302 clinical medicine030212 general & internal medicineChildWaste Management and DisposalHBV infectionlcsh:Environmental sciencesSchools Medicallcsh:GE1-350Anti-HBs titreHepatitis BVaccinationCohortFemaleAdultmedicine.medical_specialtyHepatitis B virusAdolescent030106 microbiologyHBV infection HBV vaccination Anti-HBs titre Healthcare students postgraduate medical studentsHealthcare studentslcsh:Agriculture03 medical and health sciencesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodiesStudentsEcology Evolution Behavior and SystematicsHBV vaccinationHepatitis B virusHepatitis B Surface Antigensbusiness.industrySettore MED/44 - Medicina Del Lavorolcsh:SPublic Health Environmental and Occupational HealthOdds ratioConfidence intervalpostgraduate medical studentsCross-Sectional StudiesImmunologyObservational studybusinessBiomarkersFollow-Up Studies
researchProduct

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Update of the statements on biology and clinical impact of occult hepatitis B virus infection

2019

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

0301 basic medicineOccult HBV infectionHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaHbv reactivationMEDLINEHBV reactivationOBImedicine.disease_cause03 medical and health sciences0302 clinical medicineHBV S variantRisk FactorsmedicineHumansHepatitis B AntibodiesIntensive care medicineComputingMilieux_MISCELLANEOUSHepatitis B virusHepatitis B Surface AntigensHepatologyHBV cccDNALiver Neoplasmsvirus diseasesHBV cccDNA; HBV reactivation; HBV S variants; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infectionHBV S variantsHepatitis Bmedicine.diseaseOccultdigestive system diseases3. Good healthHBV S variants; HBV cccDNA; HBV reactivation; HBV transmission; Hepatocellular carcinoma; OBI; Occult HBV infection030104 developmental biologyLiverHepatocellular carcinomaDNA Viral030211 gastroenterology & hepatologyHBV transmission[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Use of the polymerase chain reaction to demonstrate hepatitis B virus DNA in serum of children with chronic hepatitis B.

1992

The polymerase chain reaction was used to investigate the presence of hepatitis B virus DNA in sera of 61 children with chronic hepatitis B and negative results on dot biot hybridization tests. Our results demonstrate that most chronic carriers of hepatitis B surface antigen in childhood have hepatitis B virus DNA detectable by polymerase chain reaction in their serum and must be considered infectious.

AdolescentHepatitis B virus DNA polymeraseHepatitis B virus DNAmedicine.disease_causePolymerase Chain ReactionVirusHepatitis B virus PRE betalaw.inventionChronic hepatitislawMedicineHumansHepatitis B e AntigensHepatitis B AntibodiesChildPolymerase chain reactionHepatitis B virusbiologybusiness.industryInfantbiology.organism_classificationHepatitis BVirologyHepadnaviridaeChild PreschoolPediatrics Perinatology and Child HealthChronic DiseaseDNA ViralbusinessThe Journal of pediatrics
researchProduct

Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.

1988

Four-hundred and seventeen patients undergoing open-heart surgery were followed for more than 9 months after transfusion. All 2270 blood units transfused had alanine aminotransferase levels less than or equal to 30 U/l. Blood units positive for antibodies to hepatitis B core antigen (anti-HBc) were more frequently associated with recipient hepatitis non-A, non-B (HNANB) (13.7%) than anti-HBc-negative units (4.2%) (p less than 0.001). The frequency of HNANB among recipients of at least 1 anti-HBc-positive blood unit (8/79, 10.1%) was fivefold greater than among recipients of exclusively anti-HBc-negative blood units (7/338, 2.1%) (p less than 0.01). In this study the exclusion of donors posi…

AdultAdolescentHepatitis Viral HumanImmunologyBlood DonorsAntigenImmunology and AllergyMedicineHumansAlanine aminotransferaseHepatitis B AntibodiesAgedHepatitisbiologybusiness.industryIncidence (epidemiology)virus diseasesTransfusion ReactionAlanine TransaminaseHematologyMiddle Agedmedicine.diseaseHepatitis B Core AntigensHepatitis Cdigestive system diseasesImmunologybiology.proteinBlood unitsAntibodybusinessDonor screeningHepatitis b coreTransfusion
researchProduct

Active immunization of homosexual men using a recombinant hepatitis B vaccine

1989

Twenty homosexual men [13 anti-human immunodeficiency virus (HIV)-positive, seven anti-HIV negative] without HBsAg, anti-HBs, and anti-HBc were vaccinated with three 20 micrograms doses of a recombinant hepatitis B vaccine. All anti-HIV-positive homosexuals were nonresponders independent of the initial number of CD4-positive cells. Among seven anti-HIV-negative individuals, five responded. After three doses of the vaccine, CD4-positive cells fell in anti-HIV positive individuals by 22.4%. A similar fall in CD4-positive cells of an average 24.9% was noted in 17 matching, but nonvaccinated, anti-HIV-positive homosexuals. The study indicates that the efficacy of vaccination in anti-HIV-positiv…

AdultCD4-Positive T-LymphocytesMaleViral Hepatitis VaccinesHepatitis B virusHBsAgAdolescentmedicine.disease_causeActive immunizationVirusVirologyHIV Seropositivitymental disordersHumansMedicineHepatitis B AntibodiesHepatitis B virusVaccinesVaccines SyntheticHepatitis B Surface Antigensbiologybusiness.industryvirus diseasesHomosexualityMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseVirologyBlood Cell CountVaccinationInfectious DiseasesHepadnaviridaeImmunologybiology.proteinAntibodybusinesspsychological phenomena and processesJournal of Medical Virology
researchProduct

HLA-DRB1*1301 AND *1302 protect against chronic hepatitis B

1997

Abstract Background/Aims: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection. Methods: Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were d…

AdultHepatitis B virusRemission SpontaneousPopulationEnzyme-Linked Immunosorbent AssayMajor histocompatibility complexmedicine.disease_causePolymerase Chain ReactionHLA-DQ alpha-ChainsVirusHLA-DQ AntigensMHC class ImedicineHumansSerologic TestsProspective StudiesHepatitis B AntibodieseducationHLA-DRB1AllelesHepatitis B viruseducation.field_of_studyMHC class IIHepatitis B Surface AntigensHepatologybiologyHLA-DR AntigensHepatitis BVirologyChronic infectionImmunoglobulin GChronic DiseaseDNA ViralImmunologybiology.proteinHLA-DRB1 ChainsJournal of Hepatology
researchProduct

High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance

2004

The emergence of drug-resistant virus in hepatitis B virus patients treated with lamivudine is well documented. However. its clinical impact in the long-term treatment of anti-HBe positive compensated cirrhotic patients is not well known. In this study, we treated 22 consecutive patients with anti-HBe compensated cirrhosis with lamivudine for a median period of 42 months. All patients responded to lamivudine, but viral breakthrough occurred in 13 patients (59%) between 9 and 42 months of therapy due to the emergence of a mutant strain. During the follow-up, 11 developed hepatocellular carcinoma. Of these, 10 occurred soon after the emergence of viral resistance, generally showing aggressive…

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyCarcinoma HepatocellularCirrhosisLAMIVUDINEmedicine.disease_causeRisk AssessmentGastroenterologyVirusVirologyInternal medicineDrug Resistance ViralHumansMedicineHepatitis B e AntigensHEPATOCELLULAR CARCINOMAHepatitis B AntibodiesCIRRHOISIS; HEPATOCELLULAR CARCINOMA; LAMIVUDINE; HEPATITIS B; PRE-CORE MUTANTHepatitis B virusCirrhosiHepatologybusiness.industryCIRRHOISISLamivudineMiddle AgedHepatitis Bmedicine.diseaseHepatitis B Core AntigensViral BreakthroughPRE-CORE MUTANTInfectious DiseasesHepatocellular carcinomaRelative riskMutationHEPATITIS BReverse Transcriptase InhibitorsFemalePrecore mutantbusinessmedicine.drugJournal of Viral Hepatitis
researchProduct